Assessing the utilization of high‐resolution 2‐field HLA typing in solid organ transplantation

HLA typing in solid organ transplantation (SOT) is necessary for determining HLA‐matching status between donor‐recipient pairs and assessing patients’ anti‐HLA antibody profiles. Histocompatibility has traditionally been evaluated based on serologically defined HLA antigens. The evolution of HLA typing and antibody identification technologies, however, has revealed many limitations with using serologic equivalents for assessing compatibility in SOT. The significant improvements to HLA typing introduced by next‐generation sequencing (NGS) require an assessment of the impact of this technology on SOT. We have assessed the role of high‐resolution 2‐field HLA typing (HR‐2F) in SOT by retrospectively evaluating NGS‐typed pre‐ and post‐SOT cases. HR‐2F typing was highly instructive or necessary in 41% (156/385) of the cases. Several pre‐ and posttransplant scenarios were identified as being better served by HR‐2F typing. Five different categories are presented with specific case examples. The experience of another center (Temple University Hospital) is also included, whereby 21% of the cases required HR‐2F typing by Sanger sequencing, as supported by other legacy methods, to properly address posttransplant anti‐HLA antibody issues.

[1]  A. Zachary,et al.  HLA antibody detection and characterization by solid phase immunoassays: methods and pitfalls. , 2012, Methods in molecular biology.

[2]  F. Claas,et al.  The 25th anniversary of the Eurotransplant Acceptable Mismatch program for highly sensitized patients. , 2015, Transplant immunology.

[3]  R. Bray,et al.  HLA Antibody Detection With Solid Phase Assays: Great Expectations or Expectations Too Great? , 2014, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[4]  D. Mallon,et al.  Alloantibody Responses After Renal Transplant Failure Can Be Better Predicted by Donor–Recipient HLA Amino Acid Sequence and Physicochemical Disparities Than Conventional HLA Matching , 2016, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[5]  L. Turka,et al.  Primer on Transplantation , 2001 .

[6]  N. Banner,et al.  De Novo Donor HLA‐Specific Antibodies after Heart Transplantation Are an Independent Predictor of Poor Patient Survival , 2011, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[7]  D. Hricik Primer on Transplantation: Hricik/Primer on Transplantation , 2011 .

[8]  Jennifer R. Zitzner,et al.  HLA-DQ Barrier: Effects on cPRA Calculations , 2013, Transplantation.

[9]  R. Vaughan,et al.  The Clinical Spectrum of De Novo Donor‐Specific Antibodies in Pediatric Renal Transplant Recipients , 2014, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[10]  M. Bettinotti,et al.  OR5 Donor specific antibody (DSA) assessments using HLA P groups: The devil is in the details , 2018, Human Immunology.

[11]  P W Nickerson,et al.  Class II HLA Epitope Matching—A Strategy to Minimize De Novo Donor‐Specific Antibody Development and Improve Outcomes , 2013, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[12]  M. Gerbase-DeLima,et al.  Antibodies against denatured HLA class II molecules detected in luminex-single antigen assay. , 2013, Human immunology.

[13]  F. Grumet,et al.  Donor-specific antibody against denatured HLA-A1: clinically nonsignificant? , 2011, Human immunology.

[14]  G. Ghiggeri,et al.  Posttransplant De Novo Donor‐Specific HLA Antibodies Identify Pediatric Kidney Recipients at Risk for Late Antibody‐Mediated Rejection , 2012, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[15]  N. Weiss,et al.  HLA molecular epitope mismatching and long-term graft loss in pediatric heart transplant recipients. , 2015, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[16]  C. Hurley,et al.  Definitions of histocompatibility typing terms: Harmonization of Histocompatibility Typing Terms Working Group. , 2011, Human immunology.

[17]  M. Carby,et al.  De novo donor HLA-specific antibodies predict development of bronchiolitis obliterans syndrome after lung transplantation. , 2014, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[18]  M. Sypek,et al.  HLA Epitope Matching in Kidney Transplantation: An Overview for the General Nephrologist. , 2017, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[19]  A. Israni,et al.  OPTN/SRTR 2016 Annual Data Report: Kidney , 2018, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[20]  A. Papazoglou,et al.  Determining performance characteristics of an NGS‐based HLA typing method for clinical applications , 2016, HLA.

[21]  A. Webster,et al.  Consensus Guidelines on the Testing and Clinical Management Issues Associated With HLA and Non-HLA Antibodies in Transplantation , 2013, Transplantation.

[22]  A. Innocente,et al.  Heart transplantation with donor-specific antibodies directed toward denatured HLA-A*02:01: a case report. , 2011, Human immunology.

[23]  C. Hurley,et al.  Continue to focus clinical decision-making on the antigen recognition domain for the present. , 2019, Human immunology.

[24]  J. Friedewald,et al.  Sensitization in Transplantation: Assessment of Risk (STAR) 2017 Working Group Meeting Report , 2018, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[25]  J. Friedewald,et al.  Should HLA Mismatch Acceptability for Sensitized Transplant Candidates Be Determined at the High‐Resolution Rather Than the Antigen Level? , 2015, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[26]  C. Roufosse,et al.  De Novo DQ Donor-Specific Antibodies Are Associated With a Significant Risk of Antibody-Mediated Rejection and Transplant Glomerulopathy , 2012, Transplantation.

[27]  W. Bodmer,et al.  Nomenclature for factors of the HLA system, 2010 , 2010, Tissue antigens.

[28]  René J Duquesnoy,et al.  HLA epitope based matching for transplantation. , 2014, Transplant immunology.

[29]  M. Torres,et al.  Nomenclature for factors of the HLA system. , 2011, Bulletin of the World Health Organization.

[30]  H. Gebel,et al.  Of Cells and Microparticles: Assets and Liabilities of HLA Antibody Detection. , 2018, Transplantation.